ArticleCardiovascular diabetology2025
Prognostic role of sarcopenia in heart failure patients.
Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Effect of Baduanjin Exercise and Resistance Band Training on Sarcopenia in the Elderly: A Randomized Controlled Trial.Medical science monitor : international medical journal of experimental and clinical research · 2026Trial
- Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity.Internal and emergency medicine · 2026Article
- The Association of NT-proBNP With Maximum Tongue Pressure After Cardiac Surgery: A Cross-Sectional Study.Journal of oral rehabilitation · 2026Article
- Diabetes-related differences in body composition and their prognostic value among patients with heart failure and preserved ejection fraction: a cardiac-MRI-based study.Cardiovascular diabetology · 2026Article
- Skeletal and cardiac muscle longitudinal associations in the Baltimore Longitudinal Study of Aging (BLSA).BMC medicine · 2026Article
- Global trends and projections in cardiovascular disease-related heart failure, 1990-2050: an analysis of the Global Burden of Disease 2021 data.Internal and emergency medicine · 2026Article
- Prognostic Role of High-Sensitivity C-Reactive Protein/Albumin Ratio in Heart Failure Patients.Biomedicines · 2026Article
- Association of Vericiguat with Improvement in Functional Abilities and Comprehensive Geriatric Assessment in Elderly Patients with Worsening Heart Failure.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Correction: Prognostic role of sarcopenia in heart failure patients.Cardiovascular diabetology · 2026Article
- Cardiovascular remodeling: key mechanisms and clinical implications linking sarcopenia and heart failure.Frontiers in medicine · 2026Review
- Development and external validation of a composite biomarker-based machine learning model for sarcopenia risk stratification in patients with cardiovascular disease.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimSarcopenia is common in heart failure (HF) patients; however, there are no data regarding the possible long-term prognostic role of sarcopenia in younger adults with chronic HF without malnutrition. The aim of this study was to examine the long-term prognostic role of sarcopenia in predicting major adverse cardiac events (MACE) in outpatients with chronic HF.
methodsIn the present retrospective analysis, 670 subjects with HF were enrolled. MACE (non-fatal ischemic stroke, non-fatal myocardial infarction, cardiac revascularization or coronary bypass surgery, and cardiovascular death) and total mortality occurrence were evaluated during a mean follow-up of 4.7 years.
resultsIn the entire population, 340 patients were sarcopenic and 330 were not sarcopenic. In patients without sarcopenia, the observed MACE were 2.1 events/100 patient-year; while in the sarcopenic group there were 13.3 events/100 patient-year (p < 0.001). The multivariate analysis model confirmed that sarcopenia increase the risk of MACE by a factor of 8.6. Patients with sarcopenia had also a higher incidence of total mortality (p < 0.001) than patients without sarcopenia.
conclusionsPatients with chronic HF that suffered from sarcopenia show a higher risk of MACE and total mortality, independently by their chronological age.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.